Net revenue declined sharply year-over-year due to lower supplement sales and no diagnostic services revenue. The company reported a $5.4 million net loss from continuing operations and faces significant liquidity and going concern risks, while focusing on genomics and new diagnostics commercialization.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.